Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
293,294 Several new RNA therapeutics are in late-stage clinical trials, such as mRNA-1944 (NCT03829384) 295 and NTLA-2001 (NCT06128629)
Its powerful ability to neutralize damaging free radicals and aid in detoxification makes it a key component in both preventive health care and anti-aging regimens
Why it matters: Our results provide both experimental and molecular evidence that JH positively regulates maternal care after oviposition offering new insights into the hormonal basis and evolutionary diversification of parental care in insects
369 developed a gold nanoparticle-mediated drug delivery platform for the co-delivery of doxorubicin and polo-like kinase 1 (Plk1) siRNA, offering an adaptable and straightforward platform for studying drug-siRNA combinations in cancer treatment
